Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase NA 3Phase 1 3Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Skin Neoplasms 1Sarcoma 1Melanoma 1Lymphatic Metastasis 1

Interventions

pembrolizumab 257Cyclophosphamide 241Specimen Handling 198fludarabine 173Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 120Carboplatin 97Radiotherapy 92Paclitaxel 85venetoclax 82Cisplatin 80Gemcitabine 79fludarabine phosphate 78Injections 68Ipilimumab 64Dexamethasone 62atezolizumab 59Bevacizumab 58Cetuximab 57Radiation 55Fluorouracil 55Azacitidine 55durvalumab 54Radiosurgery 52Temozolomide 47Rituximab 44Oxaliplatin 44Docetaxel 44Irinotecan 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Propranolol × 1 year × Clear all
NCT07353294 2026-04-22

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1 Enrolling by invitation
12 enrolled

Lymphatic Metastasis

NCT05968690 2025-09-18

Naltrexone and Propranolol Combined With Immunotherapy

Rutgers, The State University of New Jersey

Phase 1 Recruiting
12 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT06670976 2025-08-26

Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma

Roswell Park Cancer Institute

Phase 1 Withdrawn
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡